LILRB4 and acute myeloid leukemia: Although the low expression of PD-L1/2 in AML impedes application of anti-PD-1 blockade, these findings underlying the significance of combining FTO inhibitors or anti-LILRB4 agents and HMAs for myeloid malignancies.